Abstract: A catheter system for preventing and treating restenosis in coronary or peripheral arteries, in a single vessel or in a bifurcation, which comprises, at least, one occlusion-infusion catheter (10) fitted with a balloon (11) disposed in the distal portion and inflatable through a lumen (12) disposed in the proximal portion of said occlusion-infusion catheter (10), the surface of said occlusion-infusion catheter (10) having perforations intended for inserting and sliding out the guide-wire (13), and one or more perforations (14) on the distal end of the balloon (11) to release the drug; and, at least, one occlusion catheter (20) fitted with a balloon (21) disposed in the distal portion and inflatable through a lumen (22) disposed in the proximal portion of said of said occlusion catheter (20), and perforations on the surface intended for inserting and sliding out the guide-wire (23), is described.

Abstract: Pharmaceutical compositions containing nanomaterials useful for treating restenotic lesions, which comprise nanomaterials containing one or more antiproliferative agents for treatment of intra-stent restenotic lesions by means of a local infusion, providing the increase in adhesion, penetration, and diffusion of the nanomaterials that contain the antiproliferative active agent in the tissue responsible for the neointimal hyperplasia, are described.

Abstract: A stent is described that releases medicamentuous composition to prevent and treat restenosis and the fabrication process that comprehends between 10.0 to 500.0 Ug/cm2 of the surface of the stent coated with rapamicyn (sirolismus) or analogous and between 0.01 to 20.0 Ug/mm2 of the surface of the stent coated with paclitaxel or analogous.